For the first time, EPGL is revealing specifically that it has developed technology for an "Autofocus" contact lens with CooperVision, Inc.
"We know we are ahead of Google and Novartis because Novartis executives reached out to us in 2013. We declined because we were already ahead and inventing new electronics for contact lenses at that point," said David Markus , Ph.D. "We posted proof of this request in 2014," Markus added. "We also posted an example of a recent patent filing so that investors could verify that too."
"The investment community has been asking for specifics on what we possess and here you go," said Michael Hayes , CEO of EPGL. "You have the CEO of a $280 billion company publicly stating that 'Autofocus' contact lens technology is worth $10 to $50 billion annually. EPGL owns key 'Autofocus' technology that is likely to beat Novartis and Google to market. Given that fact, is our present 5 cent per share stock price a bargain right now? Yes I believe it is. Will it remain at this level as the clock ticks at the USPTO? No I do not believe so," added Hayes. "With this news EPGL is going to be discovered by more investors and I believe we may surpass .88 cents or even $1 .00+ as our patents pending progress. Current EPGL investors are in at just the right time in my opinion."
Zacks Equity Research , recently stated; "We believe The Cooper Companies is poised to gain significant market traction, once it receives the exclusive license of EP Global's technologies."
